Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

New medicines, access to treatments, infectious disease monitoring, and more are on the table.View on euronews ...

Despite this, India faces significant challenges in ensuring the development, affordability, and accessibility of orphan ...

Amtagvi Infusions: A total of 146 patients have been infused with Amtagvi since the first commercial infusion in April 2024, including 25 patients infused in the second quarter, 82 patients infused in ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Following a three-hour hearing, European lawmakers opted on Wednesday night to defer their decision on Olivér Várhelyi's nomination as EU Commissioner for health and animal Welfare, questioning his ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

The most immediate economic worry for Europe will be tariffs. Trump has floated the idea of replacing the federal income tax with across-the-board tariffs ranging from 10% to 20%. Higher tariffs will ...

PARIS, France and TARRYTOWN, NY, USA I 6, 2024 I The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis ...

The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...